Business Description
Orient Pharma Co Ltd
ISIN : TW0004166004
Total Employee Number:
160Description
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.2 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | 0.51 | |||||
Interest Coverage | 33.77 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 10.96 | |||||
Beneish M-Score | -2.72 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 30.5 | |||||
3-Year EBITDA Growth Rate | 107.3 | |||||
3-Year Book Growth Rate | 21.9 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 80.12 | |||||
9-Day RSI | 70.17 | |||||
14-Day RSI | 64.22 | |||||
3-1 Month Momentum % | -7.25 | |||||
6-1 Month Momentum % | -14.77 | |||||
12-1 Month Momentum % | -35.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.73 | |||||
Quick Ratio | 5.01 | |||||
Cash Ratio | 3.35 | |||||
Days Inventory | 187.02 | |||||
Days Sales Outstanding | 59.3 | |||||
Days Payable | 34.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.1 | |||||
Shareholder Yield % | -5.06 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 56.47 | |||||
Operating Margin % | 19.07 | |||||
Net Margin % | 14.88 | |||||
EBITDA Margin % | 27.72 | |||||
FCF Margin % | 22.16 | |||||
OCF Margin % | 25.7 | |||||
ROE % | 9.91 | |||||
ROA % | 7.76 | |||||
ROIC % | 10.28 | |||||
3-Year ROIIC % | 46.8 | |||||
ROC (Joel Greenblatt) % | 19.69 | |||||
ROCE % | 10.89 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 30.39 | |||||
PE Ratio without NRI | 29.76 | |||||
Price-to-Owner-Earnings | 24.01 | |||||
PS Ratio | 4.54 | |||||
PB Ratio | 2.58 | |||||
Price-to-Tangible-Book | 3.08 | |||||
Price-to-Free-Cash-Flow | 20.37 | |||||
Price-to-Operating-Cash-Flow | 17.56 | |||||
EV-to-EBIT | 24.46 | |||||
EV-to-EBITDA | 15.91 | |||||
EV-to-Revenue | 4.42 | |||||
EV-to-FCF | 18.5 | |||||
Price-to-GF-Value | 0.6 | |||||
Price-to-Projected-FCF | 2.44 | |||||
Price-to-Graham-Number | 2.02 | |||||
| Price-to-Net-Current-Asset-Value | 7.47 | |||||
| Price-to-Net-Cash | 26.15 | |||||
Earnings Yield (Greenblatt) % | 4.09 | |||||
FCF Yield % | 4.69 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Orient Pharma Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 1,400.378 | ||
| EPS (TTM) (NT$) | 0.895 | ||
| Beta | -0.059 | ||
| 3-Year Sharpe Ratio | 0.11 | ||
| 3-Year Sortino Ratio | 0.17 | ||
| Volatility % | 36.3 | ||
| 14-Day RSI | 64.22 | ||
| 14-Day ATR (NT$) | 0.892661 | ||
| 20-Day SMA (NT$) | 25.3625 | ||
| 12-1 Month Momentum % | -35.73 | ||
| 52-Week Range (NT$) | 22.3 - 37.7 | ||
| Shares Outstanding (Mil) | 243.04 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Orient Pharma Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Orient Pharma Co Ltd Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Orient Pharma Co Ltd Frequently Asked Questions
What is Orient Pharma Co Ltd(ROCO:4166)'s stock price today?
The current price of ROCO:4166 is NT$27.20. The 52 week high of ROCO:4166 is NT$37.70 and 52 week low is NT$22.30.
When is next earnings date of Orient Pharma Co Ltd(ROCO:4166)?
The next earnings date of Orient Pharma Co Ltd(ROCO:4166) is .
Does Orient Pharma Co Ltd(ROCO:4166) pay dividends? If so, how much?
Orient Pharma Co Ltd(ROCO:4166) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Orient Pharma Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers